Development of Uniform Protocol for Alopecia Areata Clinical Trials

James A. Solomon[1,2,3]

Developing a successful treatment for alopecia areata (AA), clearly has not been at the forefront of the agenda for new drug/device development among the pharmaceutical and medical device industry. The National Alopecia Areata Foundation (NAAF), a patient advocacy group, initiated a plan to facilitate and drive clinical research toward finding safe and efficacious treatments for AA. As such, Alopecia Areata Uniform Protocols for clinical trials to test new treatments for AA were developed. The design of the uniform protocol is to accomplish the development of a plug-and-play template as well as to provide a framework wherein data from studies utilizing the uniform protocol can be compared through consistency of inclusions/exclusions, safety, and outcome assessment measures. A core uniform protocol for use by pharmaceutical companies in testing proof of concept for investigational products to treat AA. The core protocol includes standardized title, informed consent, inclusion/exclusion criteria, disease outcome assessments, and safety assessments. The statistical methodology to assess successful outcomes will also be standardized. The protocol as well as the informed consent form has been approved in concept by Liberty IRB and is ready to present to pharmaceutical companies.

The Journal of Investigative Dermatology Symposium (2015) **17,** 63–66; doi:10.1038/jidsymp.2015.45

INTRODUCTION

Developing a successful treatment for alopecia areata (AA) clearly has not been at the forefront of the agenda for new drug/device development among the pharmaceutical and medical device industry. Currently, no Federal Food and Drug Administration (FDA) approved therapy exists (Shapiro *et al.*, 1997; Lachgar *et al.*, 1998; Wiseman *et al.*, 2001; Olsen *et al.*, 2004; Blume-Peytavi *et al.*, 2011; Gilhar *et al.*, 2012). The National Alopecia Areata Foundation (NAAF), a patient advocacy group, initiated a plan to facilitate and drive clinical research toward finding safe and efficacious treatments for AA. NAAF, following FDA Guidelines (FDA, 2010), obtained support in principle from the FDA, to develop Alopecia Areata Uniform Protocols for clinical trials to test new treatments for AA. The design of the uniform protocol is meant to accomplish two overall goals: firstly, the uniform protocol is to be a plug-and-play template to entice biopharmaceutical and medical device companies to test medications and devices on AA. Secondly, the AAUP is to be a framework wherein data from clinical trials for the treatment of AA can be easily compared through consistency of inclusions/exclusions, safety, and outcome assessment measures.

RESULTS

A core protocol for a pharmaceutical investigative product proof of concept was developed and approved by the SAC.

The title accepted is ''Uniform Core Protocol for Phase (II /III) of A Double-Blind, Vehicle Controlled, Randomized, Multi-Center Study to Evaluate the Safety and Therapeutic Efficacy of <ENTER IP> Treatment of Adult Patients with Moderate to Severe Scalp Alopecia Areata.''

The calculation of power follows d1:d2: v (Treatment Dose 1: Treatment Dose 2: Vehicle) For a *P*-value percentage difference between treatment Dose 1 (d1), Dose 2 (d2), and vehicle (veh)-treated subjects on the primary efficacy end point, treatment d1, d2, and veh-treated subjects will be required to provide π% power with a two-sided test at a significance level of 0.05. Screened: d1 $+$d2 $+$v$+\sigma$ Enrolled (Randomized): (d1 $+$d2 $+$v$+\sigma$) * % Planned Complete: d1 $+$d2 $+$v. (Dell *et al.*, 2002).

Primary objective is

The primary objective is to assess the safety and therapeutic efficacy of a 24-week regimen of administration of investigational products (IP) with x treatment frequency, in adult subjects with chronic moderate-to-severe scalp AA.

Secondary objectives include

Assessment of the durability of the response over a 12-week post-treatment period of observation; the subjects' perceptions of their scalp disease with treatment, and upon withdrawal of treatment, in relationship to baseline; the change from

[1]*Ameriderm Research, Ormond Beach, Florida, USA;* [2]*Department of Dermatology, University of Central Florida College of Medicine, Orlando, Florida, USA and* [3]*Department of Medicine, University of Illinois College of Medicine, Urbana, Illinois, USA*

Correspondence: James A. Solomon, Ameriderm Research, 725 West Granada Boulevard, Suite 44, Ormond Beach, Florida 32174, USA.
E-mail: drjsolomon@amerideremresearch.com

Abbreviations: AA, Alopecia areata; AT, Alopecia totalis; AU, Alopecia universalis; FDA, Federal Food and Drug Administration (USA); ICF, Informed Consent Form; IP, Investigative Product; NAAF, National Alopecia Areata Foundation; SAC, Scientific Advisory Committee; SALT, Severity of Alopecia Tool



Figure 1. Map of core protocol for pharmaceutical investigative drug. The pharmaceutical company would edit this protocol with input specific to the investigative drug.

baseline of the number and width of terminal hairs in the target site using digital photography; and IP-specific changes in the biomarker associated with IP.

Inclusion criteria include
Subjects >18 years of age with a diagnosis of scalp AA and at least 25% scalp hair loss due to AA, for at least 6 months up to 2 years duration. All subjects taking thyroid medication or hormonal therapy must be on a stable dose for 6 months and maintain such throughout the study. Female subjects who are pregnant or who are nursing or plan pregnancy during the study period are restricted from participation.

Exclusion criteria include
Less than 25% scalp AA involvement; any co-existent androgenetic alopecia; prior treatment with IP; active scalp inflammation; history of systemic or cutaneous medical, or psychiatric disease which will put patient at risk or interfere with assessments.

Disease outcome assessments include
Severity of Alopecia Tool (SALT) score (Figure 1); digital photography; IP-related biomarkers, subject oriented AA assessments (Figure 2) Skindex, and Mendoza AA Qol Burden of Disease Questionnaire.

Safety assessments include
Adverse event history, changes in concomitant medications and/or diseases, physical exam, vital signs, electrocardiogram, chest X-ray, safety blood and urine labs, and IP-specific safety labs.



Olsen/Canfield

Salt score			
Site:	Subject:	Visit:	Date:
Quadrant	Percentage involved	Multiplier	Score
Left side		0.18	
Right side		0.18	
Top		0.40	
Back		0.24	
Total			

Figure 2. Severity of Alopecia Tool (SALT) score methodology (Reprinted from Olsen *et al.*, 2004 with permission from the *Journal of the American Academy of Dermatology*).

Analysis
The methods of analysis will be calculated according to standard statistical methods to maintain significance based on knowledge of the investigative product or device being tested. A minimal significance of $P<0.05$ two-tailed will be maintained. Wherein possible, one should justify the number of subjects with a preliminary power calculation, as published by Dell *et al.* (2002) for calculating sample size, using the formula $n=1+2C(s/d)2$, where $n=$number to enroll, C is